SCHEMBL21027239

SCHEMBL21027239

O=C(O)Cn1c2ccccc2c(=O)c2ccc(Br)cc21

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GLA P06280 2/20 0.74
KDM4E B2RXH2 3/20 0.61
TSPO P30536 2/20 0.49
APEX1 P27695 1/20 0.49
P2RX4 Q99571 1/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.46
MARK4 Q96L34 1/20 0.45
ALDH1A1 P00352 4/20 0.45
POLB P06746 2/20 0.45
HPGD P15428 2/20 0.45
HTT P42858 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
RCE1 Q9Y256 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MAPK1 P28482 1/20 0.45
STAT3 P40763 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21027003 0.91 GLA (0.74) GLAKDM4ETSPOAPEX1P2RX4
SCHEMBL15732891 0.86 GLA (0.87) GLAKDM4EAPEX1P2RX4PTGDR2
Cridanimod SCHEMBL3372087 0.86 GLA (1.00) GLAKDM4EAPEX1P2RX4ALDH1A1
Cridanimod SCHEMBL29373385 0.86 GLA (1.00) GLAKDM4EAPEX1P2RX4ALDH1A1
Cridanimod SCHEMBL3801665 0.86 GLA (1.00) GLAKDM4EAPEX1P2RX4ALDH1A1
Cridanimod SCHEMBL3375823 0.85 GLA (0.96) GLAKDM4EAPEX1P2RX4ALDH1A1
Cridanimod SCHEMBL27895128 0.85 GLA (0.96) GLAKDM4EAPEX1P2RX4ALDH1A1
Cridanimod SCHEMBL3375819 0.85 GLA (0.96) GLAKDM4EAPEX1P2RX4ALDH1A1
SCHEMBL21027247 0.84 GLA (0.51) GLAKDM4EPTGDR2MARK4HTT
SCHEMBL27547403 0.84 KDM4E (0.72) GLAKDM4ETSPOAPEX1PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210002230-A1 OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE Stingthera, Inc. 2021-01-07 US disclosed
US-10745358-B2 Oxoacridinyl acetic acid derivatives and methods of use SILICON SWAT, INC. (US) 2020-08-18 US disclosed
US-20190161449-A1 OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE SILICON SWAT, INC. 2019-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190161449-A1 OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE STING1, IRF3, CGAS GLA 364/4885KDM4E 4553/4885TSPO 3555/4885
US-20210002230-A1 OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE STING1, IRF3, CGAS GLA 364/4885KDM4E 4553/4885TSPO 3555/4885
US-10745358-B2 Oxoacridinyl acetic acid derivatives and methods of use STING1, IRF3, CGAS GLA 364/4885KDM4E 4553/4885TSPO 3555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.